Table 2.
The epidemiological and clinical characteristics of the all patients undergoing IVF/PGT treatment.
| Characteristic | Live birth N=105 | Miscarriage N=26 | Not-implanted N=185 | p value |
|---|---|---|---|---|
| Maternal age, y, mean ± SD | 32.3 ± 4.7 | 31.6 ± 4.7 | 33.2 ± 4.7 | 0.116 |
| Paternal age, y, mean ± SD | 34.6 ± 6.1 | 34.0 ± 4.7 | 34.5 ± 5.2 | 0.896 |
| BMI, kg/m2, mean ± SD | 21.5 ± 2.5 | 21.0 ± 1.9 | 21.6 ± 2.4 | 0.315 |
| Education, n (%) | 0.903 | |||
| Senior high school degree or less | 14 (28.6) | 5 (10.2) | 30 (61.2) | |
| college degree | 78 (33.6) | 19 (8.2) | 135 (58.2) | |
| post-graduate degree | 13 (37.1) | 2 (5.7) | 20 (57.1) | |
| gravidity | 1 (0-2) | 1 (0-3) | 1 (0-2) | 0.512 |
| parity | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0.554 |
| Cycle protocols, n (%) | 0.693 | |||
| GnRH agonist protocol | 40 (32.8) | 11 (9.0) | 71 (58.2) | |
| Antagonist protocol | 57 (34.1) | 13 (7.8) | 97 (58.1) | |
| microdose flare protocol | 8 (36.4) | 1 (4.5) | 13 (59.1) | |
| Other protocol | 0 (0.0) | 1 (20.0) | 4 (80.0) | |
| Indications for PGT, n (%) | 0.538 | |||
| chromosomal abnormalities | 32 (29.6) | 12 (11.1) | 64 (59.3) | |
| Advanced age | 14 (32.6) | 2 (4.7) | 27 (62.8) | |
| Male factor | 17 (40.5) | 2 (4.8) | 23 (54.8) | |
| Recurrent implantation failure | 4 (28.6) | 2 (14.3) | 8 (57.1) | |
| Recurrent miscarriage | 15 (34.9) | 6 (14.0) | 22 (51.2) | |
| Patient request | 23 (34.8) | 2 (3.0) | 41 (62.1) | |
| Infertility type, n (%) | 0.694 | |||
| Primary | 38 (36.2) | 9 (8.6) | 58 (55.2) | |
| Secondary | 67 (31.8) | 17 (8.1) | 127 (60.2) | |
| bFSH, IU/L | 7.2 ± 2.0 | 6.8 ± 2.7 | 7.3 ± 2.4 | 0.157 |
| bLH, IU/L | 4.8 ± 2.2 | 6.1 ± 3.2 | 4.5 ± 2.1 | 0.082 |
| bEstradiol, pmol/L | 141.7 ± 75.8 | 155.7 ± 75.0 | 140.5 ± 66.0 | 0.712 |
| Gonadotropin duration, days | 10.0 ± 2.7 | 9.7 ± 1.9 | 9.8 ± 2.3 | 0.900 |
| Gonadotropin dosage, IU | 2302.7 ± 778.9 | 2422.6 ± 449.3 | 2359.0 ± 738.0 | 0.599 |
| endometrial thickness, mm | 9.3 ± 1.4 | 9.7 ± 2.0 | 9.4 ± 1.5 | 0.717 |
| FET type, n (%) | 0.617 | |||
| Natural cycle | 35 (32.1) | 7 (6.4) | 67 (61.5) | |
| HRT cycle | 70 (33.8) | 19 (9.2) | 118 (57.0) | |
| Biopsy day, n (%) | 0.004* | |||
| 5 | 35 (49.3) | 3 (4.2) | 33 (46.5) | |
| 6 | 70 (28.6) | 23 (9.4) | 152 (62.0) | |
| TE quality, n (%) | 0.099 | |||
| A | 6 (60.0) | 0 (0) | 4 (40.0) | |
| B | 75 (36.2) | 16 (7.7) | 116 (56.0) | |
| C | 24 (24.2) | 10 (10.1) | 65 (65.7) | |
| ICM quality, n (%) | 0.070 | |||
| A | 14 (38.9) | 6 (16.7) | 16 (44.4) | |
| B | 91 (32.5) | 20 (7.1) | 169 (60.4) | |
| C | 0 (0) | 0 (0) | 0 (0) | |
| Blastocyst quality, n (%) | 0.024* | |||
| Good | 14 (38.9) | 6 (16.7) | 16 (44.4) | |
| Average | 67 (37.0) | 10 (5.5) | 104 (57.5) | |
| Poor | 24 (24.2) | 10 (10.1) | 65 (65.7) |
Continuous variables were calculated by Kruskal-Wallis test, categorical variables were calculated by chi-squared test; BMI, body mass index; PGT, preimplantation genetic testing; TE, Trophectoderm; ICM, inner cell mass; bLH, basic luteinizing hormone; bFSH, basic follicle-stimulating hormone; bAMH, basic anti-Müllerian hormone; FET, frozen-thawed embryo transfer; HRT, hormone replacement therapy; *p<0.05.